ascopubs.org

Molecular stratification of response and survival of venetoclax in combination with hypomethylating agents in AML.

Analysis of real-world outcomes of IKZFmut in Philadelphia chromosome-positive ALL: A retrospective, single-institution experience.
Healio

Five-day azacitidine best among shorter hypomethylating agent regimens for low-risk MDS

Please provide your email address to receive an email when new articles are posted on . A 5-day azacitidine course had the most consistent survival benefit for low-risk MDS vs. other shorter ...
The American Journal of Managed Care

Hypomethylating Agents Impacting MDS Treatment Landscape

Salman Fazal, MD, shares opinions regarding the role of hypomethylating agents (HMAs) in treatment for patients with MDS. Ryan Haumschild, PharmD, MS, MBA:As we discuss some of the treatments, one ...
ascopubs.org

Hydroxyurea vs. hypomethylating vs. other agents in chronic myelomonocytic leukemia: A retrospective inspection of treatment strategies among 457 Mayo Clinic patients.

Maintenance therapy with azacitidine and valproic acid after allogeneic stem cell transplant in patients with high-risk myelodysplastic syndrome and acute myelogenous leukemia. QuANTUM-Wild: A phase 3 ...
Healio

Recommended treatment for high-risk myelodysplastic syndrome underused, misused

Please provide your email address to receive an email when new articles are posted on . Most patients with newly diagnosed high-risk myelodysplastic syndrome do not receive guideline-recommended ...